Tolerance and Pharmacokinetics of TQ-B3233

Inclusion Criteria: * Patients definitely diagnosed by pathology and/or cytology as BRAF mutation advanced malignant melanoma. * 18-70 years old, ECOG PS:0-1,Life expectancy of more than 3 months; * Patients treated with chemotherapy agents or surgery before being enrolled into the study need waiting for 4 weeks, 6 weeks will be needed if agents were nitrocarbamide and mitomycin C; * Main organs function is normal; * Women of childbearing potential should agree to use and utilize an adequate method of contraception (such as intrauterine device，contraceptive and condom) throughout treatment and for at least 6 months after study is stopped；the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be non-lactating；Man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped; * Patients should be voluntary and sign the informed consent before taking part in the study; Exclusion Criteria: * Patients with Malignant tumors within 5 years, except for non-melanoma skin cancer and in situ cancer; * Patients who had previously received specific BRAF inhibitors; * A variety of factors that affect oral medication (such as inability to swallow, gastrointestinal resection, chronic diarrhea, intestinal obstruction, etc.) * Patients who participated in other anticancer drug clinical trials within 4 weeks ; * Blood pressure unable to be controlled ideally by one drug(systolic pressure≥150 mmHg，diastolic pressure≥90 mmHg); * Patients with Grade 1 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias or cardiac insufficiency (including QTc≥480ms) and patients with Grade 3 or higher congestive heart failure (NYHA Classification); * Patients with non-healing wounds or fractures; * Patients with brain metastasis, spinal cord compression, cancerous meningitis, CT or MRI examination reminds patients with cerebral or soft meningeal diseases in the screening phase; * Patients with drug abuse history or unable to get rid of drugs or Patients with mental disorders; * Coagulation function abnormality: haemorrhagic tendencies (e.g. active digestive tract ulcer), or are receiving thrombolytic or anticoagulant therapy; * Patients with immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disease, or organ transplant history; * Patients with thyroid dysfunction; * Patients with concomitant diseases which could seriously endanger themselves or those who won't complete the study according to investigators; * Parents with hepatitis b surface antigen positive or HCV;